Nurix Therapeutics, Inc. is a biopharmaceutical company. It focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in San Francisco, CA.
$36.33 +3.84 (11.82%)
As of 03/05/2021 15:59:55 EST IEX book CBOE book
2021 © Stock Market MBA, Inc.